A Study to Compare the Efficacy of Fluticasone Furoate/Vilanterol Inhalation Powder With Usual Inhaled Corticosteroids (ICS)/Long Acting Beta Agonists (LABA) in Persistent Asthma

Asthma Clinical Trial

Official title:

A 6-month, Open Label, Randomised, Efficacy Study to Evaluate Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) Inhalation Powder Delivered Once Daily Via the Dry Powder Inhaler ELLIPTA™ Compared With Usual ICS/LABA Maintenance Therapy Delivered by Dry Powder Inhaler in Subjects With Persistent Asthma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02446418
• Other study ID #: 116492
• Status: Completed
• Phase: Phase 3
• Start date: July 9, 2015
• Est. completion date: July 20, 2017

Study information

• Verified date: June 2018
• Source: GlaxoSmithKline
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The combination of FF, an ICS and VI, an orally inhaled LABA has been developed as a once-daily combination therapy for the long-term maintenance treatment of asthma in adults and children >=12 years of age. Pivotal phase III studies have demonstrated the safety and efficacy of FF/VI in asthma. However, it is increasingly acknowledged that randomised clinical trials tend to be highly controlled and enrol a more highly selected subject population than is expected to be prescribed the medication post-approval. There is a need for data in a more representative population in close to a 'real life' conditions, where physicians have the ability to choose the best treatment in their view for any individual subject and adapt treatments to subjects' characteristics and response. This multi-center, open-label, randomized, parallel group study will evaluate the efficacy and safety of FF/VI compared with two usual ICS/LABA fixed combination (fluticasone propionate/salmeterol [FP/S] or budesonide/formoterol [BUD/F]) in subjects with persistent asthma, in a "close to real life" settings. FF/VI will be administered once-daily (QD) via ELLIPTA dry powder inhaler (DPI) and FP/S or BUD/F will be administered twice daily (BID) via DISKUS™ and TURBUHALER™ DPI respectively. ELLIPTA is a new powder inhaler designed to be easy to use. The total duration of subject participation will be approximately 6 months (24 weeks). ELLIPTA and DISKUS are registered trademarks of the GSK group of companies. TURBUHALER is a registered trademark of AstraZeneca.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 423
• Est. completion date: July 20, 2017
• Est. primary completion date: July 20, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Informed consent: Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the consent form and in this protocol.

• Gender and Age: Male or female subjects aged >=18 and <=75years of age at Screening visit.

Female subject is eligible to participate if she is not pregnant (as confirmed by a negative urine human chorionic gonadotrophin [hCG] test), not lactating, and at least one of the following conditions applies:

Non-reproductive potential defined as: Pre-menopausal females with one of the following - Documented tubal ligation; Documented hysteroscopic tubal occlusion procedure with follow-up confirmation of bilateral tubal occlusion; Hysterectomy; Documented Bilateral Oophorectomy. Postmenopausal defined as 12 months of spontaneous amenorrhea (in questionable cases a blood sample with simultaneous follicle stimulating hormone [FSH] and estradiol levels consistent with menopause [refer to laboratory reference ranges for confirmatory levels]); Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the highly effective contraception methods if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrolment.

Reproductive potential and agrees to follow one of the options listed below in the GSK Modified List of Highly Effective Methods for Avoiding Pregnancy in Females of Reproductive Potential (FRP) requirements from 30 days prior to the first dose of study medication and until Week 24.

GSK Modified List of Highly Effective Methods for Avoiding Pregnancy in FRP:

This list does not apply to FRP with same sex partners, when this is their preferred and usual lifestyle or for subjects who are and will continue to be abstinent from penile-vaginal intercourse on a long term and persistent basis: Contraceptive subdermal implant that meets the Standard Operating Procedure (SOP) effectiveness criteria including a <1percent rate of failure per year, as stated in the product label; Intrauterine device or intrauterine system that meets the SOP effectiveness criteria including a <1 percent rate of failure per year, as stated in the product label; Oral Contraceptive, either combined or progestogen alone; Injectable progestogen; Contraceptive vaginal ring; Percutaneous contraceptive patches; Male partner sterilization with documentation of azoospermia prior to the female subject's entry into the study, and this male is the sole partner for that subject; Male condom combined with a vaginal spermicide (foam, gel, film, cream, or suppository); These allowed methods of contraception are only effective when used consistently, correctly and in accordance with the product label. The investigator is responsible for ensuring that subjects understand how to properly use these methods of contraception.

• Type of subject: Subjects with documented physician's diagnosis of asthma >=1 year, unsatisfactorily controlled asthma (ACT <20 at Screening and Randomisation visit) treated by ICS alone and intended to be treated by ICS/LABA maintenance therapy; France Only: A subject will be eligible for inclusion in this study only if either affiliated to or a beneficiary of a Social Security category.

• Current Asthma Therapy: All subjects must be prescribed maintenance therapy and receiving ICS alone without LABA for at least 4 weeks prior to Randomisation visit; Other background asthma medication such as anti-leukotrienes or theophylline is permitted as an alternative to ICS alone, if initiated at least 4 weeks prior to screening visit.

• Subject questionnaires Subjects must be able to complete the questionnaires themselves.

Exclusion Criteria:

• History of Life-threatening asthma: Defined for this protocol as an asthma episode that required intubation and/or was associated with hypercapnea, respiratory arrest or hypoxic seizures within the last 6 months before Screening and Randomisation visit.

• Subjects having a severe and unstable asthma, with ACT score < 15 at Visit 1 and at Visit 2, and/or a history of repeated severe exacerbations (3/year) and/or a severe exacerbation in the previous 6 weeks before Visit 1 and Visit 2.

• Chronic obstructive pulmonary disease (COPD) Respiratory Disease: A subject must not have current evidence or diagnosis of chronic obstructive pulmonary disease at Screening visit.

• Current or former cigarette smokers with a history of cigarette smoking of >=10 pack-years at screening [number of pack years = (number of cigarettes per day / 20) x number of years smoked (e.g., 20 cigarettes per day for 10 years, or 10 cigarettes per day for 20 years)].

• Other diseases/abnormalities: Subjects with historical or current evidence of uncontrolled or clinically significant disease at Screening and Randomisation visit. Significant is defined as any disease that, in the opinion of the Investigator, would put the safety of the subject at risk through participation, or which would affect the efficacy or safety analysis if the disease/condition exacerbated during the study.

• Subjects with a history of adverse reaction including immediate or delayed hypersensitivity to any intranasal, inhaled, or systemic corticosteroid and LABA therapy and to components of the inhalation powder (e.g., lactose, magnesium stearate) at Screening and Randomisation visit. In addition, subjects with a history of severe milk protein allergy that, in the opinion of the Investigator, contraindicates the subject's participation will also be excluded.

• Investigational Medications: A subject must not have used any investigational drug within 30 days prior to Randomisation visit or within five half-lives (t½) of the prior investigational study (whichever is longer of the two), (if unsure discuss with the medical monitor prior to screening).

• Chronic user of systemic corticosteroids: A subject who, in the opinion of the Investigator, is considered to be a chronic user of systemic corticosteroids for respiratory or other indications (if unsure discuss with the medical monitor prior to screening) at Screening visit.

• Subjects treated by the monoclonal antibody omalizumab or mepolizumab at Visit 1. Treatment with omalizumab or mepolizumab is not allowed during the study.

• Subjects involved in other clinical trials at Screening visit.

• Affiliation with Investigator Site: Is an investigator, sub-investigator, study coordinator, employee of a participating investigator or study site, or immediate family member of the aforementioned that is involved in this study.

• Subjects who plan to move away from the geographical area where the study is being conducted during the study.

Related Conditions & MeSH terms

• Asthma

Intervention

Drug:
• Fluticasone Furoate
FF 92 mcg or 184 mcg blended with lactose administered once daily via ELLIPTA DPI
• Vilanterol
Vilanterol 22 mcg blended with lactose and magnesium stearate administered once daily via ELLIPTA DPI
• Fluticasone propionate
FP 250 mcg or 500 mcg blended with lactose administered twice daily via DISKUS DPI
• Salmeterol
Salmeterol 50 mcg blended with lactose administered twice daily via DISKUS DPI
• Budesonide
Budesonide 200 mcg or 400 mcg blended with lactose administered twice daily via TURBUHALER DPI
• Formoterol Fumarate
Formoterol Furoate 6 mcg or 12 mcg blended with lactose administered twice daily via TURBUHALER DPI

Locations

Country	Name	City	State
France	GSK Investigational Site	Amiens
France	GSK Investigational Site	Angers
France	GSK Investigational Site	Avelin
France	GSK Investigational Site	Bassussarry
France	GSK Investigational Site	Beauzelle
France	GSK Investigational Site	Bécon les Granits
France	GSK Investigational Site	Bersee
France	GSK Investigational Site	Beziers
France	GSK Investigational Site	Biarritz
France	GSK Investigational Site	Bourg Des Comptes
France	GSK Investigational Site	Broglie
France	GSK Investigational Site	Bruay-la-Buissière
France	GSK Investigational Site	Caen
France	GSK Investigational Site	Cannes Cedex
France	GSK Investigational Site	Carbon-Blanc
France	GSK Investigational Site	Chatellerault
France	GSK Investigational Site	Colombey-les-Belles
France	GSK Investigational Site	Coulounieix-Chamiers
France	GSK Investigational Site	Cournonterral
France	GSK Investigational Site	Dessenheim
France	GSK Investigational Site	Dijon
France	GSK Investigational Site	Dinard
France	GSK Investigational Site	Donges
France	GSK Investigational Site	Ermont cedex
France	GSK Investigational Site	Fleville Devant Nancy
France	GSK Investigational Site	Gemenos
France	GSK Investigational Site	Gondreville
France	GSK Investigational Site	Grenay
France	GSK Investigational Site	Guesnain
France	GSK Investigational Site	Hatten
France	GSK Investigational Site	Hinx
France	GSK Investigational Site	La Bouexiere
France	GSK Investigational Site	La Fôret Sur Sèvres
France	GSK Investigational Site	La Riche
France	GSK Investigational Site	Lambersart
France	GSK Investigational Site	Laval
France	GSK Investigational Site	Le Blanc-Mesnil
France	GSK Investigational Site	Limoges
France	GSK Investigational Site	Marseille cedex 03
France	GSK Investigational Site	Metz-Tessy
France	GSK Investigational Site	Montauban cedex
France	GSK Investigational Site	Montpellier
France	GSK Investigational Site	Montpellier Cedex 5
France	GSK Investigational Site	Murs-Erigne
France	GSK Investigational Site	Nancy
France	GSK Investigational Site	Nantes
France	GSK Investigational Site	Nantes
France	GSK Investigational Site	Narbonne
France	GSK Investigational Site	Nice
France	GSK Investigational Site	Obernai
France	GSK Investigational Site	Paris
France	GSK Investigational Site	Perpignan
France	GSK Investigational Site	Rosiers-d'Egletons
France	GSK Investigational Site	Rouen
France	GSK Investigational Site	Royaumeix
France	GSK Investigational Site	Saint Etienne
France	GSK Investigational Site	Saint Ouen la Rouerie
France	GSK Investigational Site	Saint-Etienne
France	GSK Investigational Site	Scorbe Clairvaux
France	GSK Investigational Site	Segré
France	GSK Investigational Site	Soulac-sur-Mer
France	GSK Investigational Site	Strasbourg
France	GSK Investigational Site	Thouars
France	GSK Investigational Site	Toul
France	GSK Investigational Site	Toulon
France	GSK Investigational Site	Toulouse
France	GSK Investigational Site	Toulouse cedex 4
France	GSK Investigational Site	Verzy
France	GSK Investigational Site	Vieux Condé
France	GSK Investigational Site	Villejuif
France	GSK Investigational Site	Wattrelos
France	GSK Investigational Site	Witry les Reims
Germany	GSK Investigational Site	Berlin
Germany	GSK Investigational Site	Berlin
Germany	GSK Investigational Site	Berlin
Germany	GSK Investigational Site	Berlin
Germany	GSK Investigational Site	Berlin
Germany	GSK Investigational Site	Delitzsch	Sachsen
Germany	GSK Investigational Site	Dortmund	Nordrhein-Westfalen
Germany	GSK Investigational Site	Geesthacht	Schleswig-Holstein
Germany	GSK Investigational Site	Leipzg	Sachsen
Germany	GSK Investigational Site	Leipzig	Sachsen
Germany	GSK Investigational Site	Leipzig	Sachsen
Germany	GSK Investigational Site	Leipzig	Sachsen
Germany	GSK Investigational Site	Leipzig	Sachsen
Germany	GSK Investigational Site	Magdeburg
Germany	GSK Investigational Site	Muenchen	Bayern
Germany	GSK Investigational Site	Muenchen	Bayern
Germany	GSK Investigational Site	Potsdam	Brandenburg
Germany	GSK Investigational Site	Rheine	Nordrhein-Westfalen
Germany	GSK Investigational Site	Schmoelln	Thueringen
Germany	GSK Investigational Site	Teuchern	Sachsen-Anhalt
Germany	GSK Investigational Site	Wallerfing	Bayern

Sponsors (1)

Lead Sponsor	Collaborator
GlaxoSmithKline

Countries where clinical trial is conducted

France,  Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change From Baseline in Asthma Control Test (ACT) Total Score at Week 12	The ACT is a validated self-completed questionnaire consisting of 5 questions that evaluate asthma control during the past 4 weeks on a 5-point categorical scale. Total scores are calculated from the sum of the scores from the 5 questions and can range from 5 to 25, with higher scores indicating better control. An ACT total score of 5 to 19 suggests that the participant's asthma is unlikely to be well controlled, whilst a score of 20 to 25 suggests that the participant's asthma is likely to be well controlled. Baseline value was the last assessment prior to randomization (Day 0). Change from Baseline was post-dose visit value minus the Baseline value. Least square mean change is presented.	Baseline and Week 12
Secondary	Change From Baseline in ACT Total Score at Week 24	The ACT is a validated self-completed questionnaire consisting of 5 questions that evaluate asthma control on a 5-point categorical scale. Total scores are calculated from the sum of the scores from the 5 questions and can range from 5 to 25, with higher scores indicating better control. An ACT total score of 5 to 19 suggests that the participant's asthma is unlikely to be well controlled, whilst a score of 20 to 25 suggests that the participant's asthma is likely to be well controlled. Baseline value was the last assessment prior to randomization (Day 0). Change from Baseline was post-dose visit value minus the Baseline value. Least square mean change is presented.	Baseline and Week 24
Secondary	Percentage of Participants With Correct Use of Device, Defined as Not Making Any Critical or Non-critical Errors, at Week 12, and at Week 24 Independently of the Use at Week 12	Participants were asked to read the appropriate package insert for their prescribed inhaler and then the investigator (or suitably qualified designee) demonstrated the proper use of the inhaler. The participant was then asked to self-administer their first dose of study treatment under the supervision of the investigator and any critical and non-critical errors were recorded. Individual instruments for assessing correct inhaler use were provided for each of the three devices used in this study.	Week 12 and Week 24